X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
oncology (9) 9
female (8) 8
male (8) 8
metastasis (7) 7
aged (6) 6
middle aged (6) 6
adult (5) 5
care and treatment (5) 5
aged, 80 and over (4) 4
cancer (4) 4
carcinoma, renal cell (4) 4
medicine & public health (4) 4
skin neoplasms - pathology (4) 4
adolescent (3) 3
analysis (3) 3
anilides - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
basal cell carcinoma (3) 3
carcinoma, basal cell - drug therapy (3) 3
cell survival (3) 3
clear cell-type renal cell carcinoma (3) 3
clinical medicine (3) 3
disease-free survival (3) 3
hematology, oncology and palliative medicine (3) 3
kaplan-meier estimate (3) 3
kidney neoplasms - pathology (3) 3
life sciences (3) 3
metastases (3) 3
pyridines - adverse effects (3) 3
risk factors (3) 3
surgery (3) 3
young adult (3) 3
anilides - administration & dosage (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
brain neoplasms - secondary (2) 2
carcinoma (2) 2
carcinoma, basal cell - secondary (2) 2
carcinoma, renal cell - drug therapy (2) 2
carcinoma, renal cell - pathology (2) 2
carcinoma, renal cell - secondary (2) 2
clinical trials (2) 2
comparative analysis (2) 2
disease progression (2) 2
double-blind method (2) 2
drug therapy (2) 2
efficacy (2) 2
health aspects (2) 2
hedgehog pathway inhibitor (2) 2
human health and pathology (2) 2
interferon (2) 2
kidney neoplasms - drug therapy (2) 2
lung neoplasms - drug therapy (2) 2
melanoma (2) 2
melanoma - secondary (2) 2
melanoma - therapy (2) 2
molecular targeted therapy (2) 2
neoplasm metastasis (2) 2
neoplasm staging (2) 2
nephrectomy (2) 2
nephrology (2) 2
open-label (2) 2
patients (2) 2
pazopanib (2) 2
prognosis (2) 2
pyridines - administration & dosage (2) 2
pyridines - therapeutic use (2) 2
quality of life (2) 2
radiotherapy (2) 2
research (2) 2
safety (2) 2
skin neoplasms - drug therapy (2) 2
skin neoplasms - therapy (2) 2
stevie (2) 2
survival (2) 2
survival rate (2) 2
therapy (2) 2
time factors (2) 2
treatment outcome (2) 2
urology (2) 2
urology & nephrology (2) 2
vismodegib (2) 2
1st-line sunitinib (1) 1
80 and over (1) 1
[sdv.mhep]life sciences [q-bio]/human health and pathology (1) 1
[sdv]life sciences [q-bio] (1) 1
abridged index medicus (1) 1
adjuvant radiation-therapy (1) 1
administration (1) 1
administration, oral (1) 1
adrenal gland neoplasms - drug therapy (1) 1
adrenal gland neoplasms - secondary (1) 1
adverse events (1) 1
age (1) 1
alanine (1) 1
alanine transaminase (1) 1
american history (1) 1
angiogenesis inhibitors - adverse effects (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Plastic and Reconstructive Surgery - Global Open, ISSN 2169-7574, 07/2017, Volume 5, Issue 7, p. e1424
Basal cell carcinoma (BCC) is the most common periocular skin cancer and can lead to significant morbidity. We assess the effectiveness of vismodegib, a... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 722 - 731
Journal Article
European Journal of Dermatology, ISSN 1167-1122, 11/2018, Volume 28, Issue 6, pp. 775 - 783
Journal Article
World Journal of Urology, ISSN 0724-4983, 12/2018, Volume 36, Issue 12, pp. 1973 - 1980
Recent trials have emphasized the importance of a precise patient selection for cytoreductive nephrectomy (CN). In 2013, a nomogram was developed for pre- and... 
Validation | Nephrology | Medicine & Public Health | Targeted therapy | Selection | Nomogram | Metastatic renal cancer | Oncology | Cytoreductive nephrectomy | Urology | THERAPY | PROGNOSTIC-FACTORS | UROLOGY & NEPHROLOGY | CANCER | Adrenal Gland Neoplasms - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Area Under Curve | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Cytoreduction Surgical Procedures | Patient Selection | Brain Neoplasms - secondary | Neoplasm Metastasis | Blood Transfusion | Lung Neoplasms - secondary | Nephrectomy | Nomograms | Adrenal Gland Neoplasms - secondary | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Kidney Neoplasms - therapy | Reproducibility of Results | Carcinoma, Renal Cell - pathology | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Survival Rate | Brain Neoplasms - drug therapy | Kidney Neoplasms - mortality | L-Lactate Dehydrogenase | Carcinoma, Renal Cell - mortality | Serum Albumin | Carcinoma, Renal Cell - secondary | Intraoperative Care | Carcinoma, Renal Cell - therapy | Kidney Neoplasms - pathology | Aged | Neoplasm Staging | Analysis | Metastasis | Carcinoma, Renal cell | Cell survival | Clinical trials | Lactic acid | Patients | Risk factors | Clear cell-type renal cell carcinoma | L-Lactate dehydrogenase | Tumors | Metastases | Clinical Medicine | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Urology and Nephrology
Journal Article
Targeted Oncology, ISSN 1776-2596, 8/2019, Volume 14, Issue 4, pp. 405 - 416
Randomized controlled trials (RCTs) have stringent inclusion criteria and may not fully represent patients seen in everyday clinical practice. Real-world data... 
Biomedicine, general | Medicine & Public Health | Oncology | EXTERNAL VALIDITY | PHASE-II TRIAL | TARGETED THERAPIES | EFFICACY | ONCOLOGY | 1ST-LINE SUNITINIB | TYROSINE KINASE INHIBITOR | OPEN-LABEL | ANTITUMOR-ACTIVITY | ELDERLY-PATIENTS | ENDOTHELIAL GROWTH-FACTOR | Carcinoma, Renal cell | Metastasis | Systematic Review
Journal Article
Journal Article
Diabetes care, ISSN 0149-5992, 02/2019, Volume 42, Issue 2, pp. 192 - 199
Journal Article